World J Gastroenterol 12(17): 2688-2693

Cholecystokinin hyperresponsiveness in functional dyspepsia

ASB Chua, Ipoh Gastro Centre, Ipoh, Perak, Malaysia

PWN Keeling, Department of Medicine, Trinity College Dublin, Ireland

Correspondence to: Andrew Seng Boon Chua, MD, MRCP, Ipoh Gastro Centre, 31, Lebuhraya Taman Ipoh, Ipoh Garden South, 31400 Ipoh, Perak, Malaysia. ten.gnirajym@auhcwerdna

Telephone: +60-5-5458488 Fax: +60-5-5457488

ASB Chua, Ipoh Gastro Centre, Ipoh, Perak, Malaysia

PWN Keeling, Department of Medicine, Trinity College Dublin, Ireland

Correspondence to: Andrew Seng Boon Chua, MD, MRCP, Ipoh Gastro Centre, 31, Lebuhraya Taman Ipoh, Ipoh Garden South, 31400 Ipoh, Perak, Malaysia. ten.gnirajym@auhcwerdna

Telephone: +60-5-5458488 Fax: +60-5-5457488

Received 2006 Mar 3; Revised 2006 Mar 12; Accepted 2006 Mar 27.

Abstract

Functional dyspepsia (FD) is a common disorder of yet uncertain etiology. Dyspeptic symptoms are usually meal related and suggest an association to gastrointestinal (GI) sensorimotor dysfunction. Cholecystokinin (CCK) is an established brain-gut peptide that plays an important regulatory role in gastrointestinal function. It inhibits gastric motility and emptying via a capsaicin sensitive vagal pathway. The effects on emptying are via its action on the proximal stomach and pylorus. CCK is also involved in the regulation of food intake. It is released in the gut in response to a meal and acts via vagal afferents to induce satiety. Furthermore CCK has also been shown to be involved in the pathogenesis of panic disorder, anxiety and pain. Other neurotransmitters such as serotonin and noradrenaline may be implicated with CCK in the coordination of GI activity. In addition, intravenous administration of CCK has been observed to reproduce the symptoms in FD and this effect can be blocked both by atropine and loxiglumide (CCK-A antagonist). It is possible that an altered response to CCK may be responsible for the commonly observed gastric sensorimotor dysfunction, which may then be associated with the genesis of dyspeptic symptoms.

Keywords: Functional dyspepsia, Cholecystokinin hyperresponsivenes, Stress, Sensorimotor dysfunction

Abstract

Footnotes

S- Editor Pan BR E- Editor Liu WF

Footnotes

References

1. Drossman DA, Corazziari E, Talley NJ, Thompson WG, Whitehead WE Rome II, The Functional Gastrointestinal Disorders. Diagnosis, Pathophysiology and Treatment; A Multinational Consensus 2nd ed. McLean VA, Degnon Associates; 2000. [PubMed][Google Scholar]
2. Feinle-Bisset C, Vozzo R, Horowitz M, Talley NJDiet, food intake, and disturbed physiology in the pathogenesis of symptoms in functional dyspepsia. Am J Gastroenterol. 2004;99:170–181.[PubMed][Google Scholar]
3. Read NWFood and hypersensitivity in functional dyspepsia. Gut. 2002;51 Suppl 1:i50–i53.[Google Scholar]
4. Camilleri MNonulcer dyspepsia: a look into the future. Mayo Clin Proc. 1996;71:614–622.[PubMed][Google Scholar]
5. Kissileff HR, Carretta JC, Geliebter A, Pi-Sunyer FXCholecystokinin and stomach distension combine to reduce food intake in humans. Am J Physiol Regul Integr Comp Physiol. 2003;285:R992–R998.[PubMed][Google Scholar]
6. Linden A, Uvnas-Moberg K, Forsberg G, Bednar I, Sodersten PPlasma concentrations of cholecystokinin octapeptide and food intake in male rats treated with cholecystokinin octapeptide. J Endocrinol. 1989;121:59–65.[PubMed][Google Scholar]
7. Baile CA, McLaughlin CL, Della-Fera MARole of cholecystokinin and opioid peptides in control of food intake. Physiol Rev. 1986;66:172–234.[PubMed][Google Scholar]
8. Raybould HE, Taché YCholecystokinin inhibits gastric motility and emptying via a capsaicin-sensitive vagal pathway in rats. Am J Physiol. 1988;255:G242–G246.[PubMed][Google Scholar]
9. Liddle RA, Morita ET, Conrad CK, Williams JARegulation of gastric emptying in humans by cholecystokinin. J Clin Invest. 1986;77:992–996.[Google Scholar]
10. Lieverse RJ, Jansen JB, Masclee AA, Lamers CBRole of cholecystokinin in the regulation of satiation and satiety in humans. Ann N Y Acad Sci. 1994;713:268–272.[PubMed][Google Scholar]
11. Lal S, McLaughlin J, Barlow J, D'Amato M, Giacovelli G, Varro A, Dockray GJ, Thompson DGCholecystokinin pathways modulate sensations induced by gastric distension in humans. Am J Physiol Gastrointest Liver Physiol. 2004;287:G72–G79.[PubMed][Google Scholar]
12. Bradwejn J, Koszycki DThe cholecystokinin hypothesis of anxiety and panic disorder. Ann N Y Acad Sci. 1994;713:273–282.[PubMed][Google Scholar]
13. Stanghellini V, Tosetti C, Paternicò A, De Giorgio R, Barbara G, Salvioli B, Corinaldesi RPredominant symptoms identify different subgroups in functional dyspepsia. Am J Gastroenterol. 1999;94:2080–2085.[PubMed][Google Scholar]
14. Sarnelli G, Caenepeel P, Geypens B, Janssens J, Tack JSymptoms associated with impaired gastric emptying of solids and liquids in functional dyspepsia. Am J Gastroenterol. 2003;98:783–788.[PubMed][Google Scholar]
15. Talley NJ, Verlinden M, Jones MCan symptoms discriminate among those with delayed or normal gastric emptying in dysmotility-like dyspepsia. Am J Gastroenterol. 2001;96:1422–1428.[PubMed][Google Scholar]
16. Gilja OH, Hausken T, Wilhelmsen I, Berstad AImpaired accommodation of proximal stomach to a meal in functional dyspepsia. Dig Dis Sci. 1996;41:689–696.[PubMed][Google Scholar]
17. Berstad A, Hauksen T, Gilja OH, Hveem K, Undeland KA, Wilhelmsen I, Haug TTGastric accommodation in functional dyspepsia. Scand J Gastroenterol. 1997;32:193–197.[PubMed][Google Scholar]
18. Tack J, Piessevaux H, Coulie B, Caenepeel P, Janssens JRole of impaired gastric accommodation to a meal in functional dyspepsia. Gastroenterology. 1998;115:1346–1352.[PubMed][Google Scholar]
19. Boeckxstaens GE, Hirsch DP, Kuiken SD, Heisterkamp SH, Tytgat GNThe proximal stomach and postprandial symptoms in functional dyspeptics. Am J Gastroenterol. 2002;97:40–48.[PubMed][Google Scholar]
20. Azpiroz FHypersensitivity in functional gastrointestinal disorders. Gut. 2002;51 Suppl 1:i25–i28.[Google Scholar]
21. Tack J, Caenepeel P, Fischler B, Piessevaux H, Janssens JSymptoms associated with hypersensitivity to gastric distention in functional dyspepsia. Gastroenterology. 2001;121:526–535.[PubMed][Google Scholar]
22. Salet GA, Samsom M, Roelofs JM, van Berge Henegouwen GP, Smout AJ, Akkermans LMResponses to gastric distension in functional dyspepsia. Gut. 1998;42:823–829.[Google Scholar]
23. Fried M, Erlacher U, Schwizer W, Löchner C, Koerfer J, Beglinger C, Jansen JB, Lamers CB, Harder F, Bischof-Delaloye A. Role of cholecystokinin in the regulation of gastric emptying and pancreatic enzyme secretion in humans. Studies with the cholecystokinin-receptor antagonist loxiglumide. Gastroenterology. 1991;101:503–511.[PubMed]
24. Lieverse RJ, Jansen JB, Masclee AA, Rovati LC, Lamers CBEffect of a low dose of intraduodenal fat on satiety in humans: studies using the type A cholecystokinin receptor antagonist loxiglumide. Gut. 1994;35:501–505.[Google Scholar]
25. Miaskiewicz SL, Stricker EM, Verbalis JGNeurohypophyseal secretion in response to cholecystokinin but not meal-induced gastric distention in humans. J Clin Endocrinol Metab. 1989;68:837–843.[PubMed][Google Scholar]
26. Von Korff RV[Properties of mitochondrial monoamine oxidase isolated from rabbit brain and liver] Biokhimiia. 1977;42:396–402.[PubMed][Google Scholar]
27. Mesquita MA, Thompson DG, Troncon LE, D'Amato M, Rovati LC, Barlow JEffect of cholecystokinin-A receptor blockade on lipid-induced gastric relaxation in humans. Am J Physiol. 1997;273:G118–G123.[PubMed][Google Scholar]
28. Bradette M, Pare P, Douville P, Morin A. Visceral perception in health and functional dyspepsia. Crossover study of gastric distension with placebo and domperidone. Dig Dis Sci. 1991;36:52–58.[PubMed]
29. Lémann M, Dederding JP, Flourié B, Franchisseur C, Rambaud JC, Jian R. Abnormal perception of visceral pain in response to gastric distension in chronic idiopathic dyspepsia. The irritable stomach syndrome. Dig Dis Sci. 1991;36:1249–1254.[PubMed]
30. Katchinsky M The role of CCK and CCK antagonists in humans esophageal and gastroduodenal motility. In: G Adler and C Beglinger. CCK antagonists in gastroenterology. Springer-Verlag Berlin; 1991. pp. 173–182. [PubMed][Google Scholar]
31. McCann MJ, Hermann GE, Rogers RCNucleus raphe obscurus (nRO) influences vagal control of gastric motility in rats. Brain Res. 1989;486:181–184.[PubMed][Google Scholar]
32. Raybould HE, Gayton RJ, Dockray GJMechanisms of action of peripherally administered cholecystokinin octapeptide on brain stem neurons in the rat. J Neurosci. 1988;8:3018–3024.[Google Scholar]
33. Raybould HE, Gayton RJ, Dockray GJCNS effects of circulating CCK8: involvement of brainstem neurones responding to gastric distension. Brain Res. 1985;342:187–190.[PubMed][Google Scholar]
34. Raybould HE, Roberts ME, Dockray GJReflex decreases in intragastric pressure in response to cholecystokinin in rats. Am J Physiol. 1987;253:G165–G170.[PubMed][Google Scholar]
35. VLW Go. The physiology of cholecystokinin. In: Gut hormones., editor. Edinburgh: Churchill Livingstone; 1978. p. 203. [PubMed]
36. Smith GP, Gibbs JSatiating effect of cholecystokinin. Ann N Y Acad Sci. 1994;713:236–241.[PubMed][Google Scholar]
37. Robinson PH, McHugh PR, Moran TH, Stephenson JDGastric control of food intake. J Psychosom Res. 1988;32:593–606.[PubMed][Google Scholar]
38. Moran TH, McHugh PRCholecystokinin suppresses food intake by inhibiting gastric emptying. Am J Physiol. 1982;242:R491–R497.[PubMed][Google Scholar]
39. Feinle C, Grundy D, Read NWEffects of duodenal nutrients on sensory and motor responses of the human stomach to distension. Am J Physiol. 1997;273:G721–G726.[PubMed][Google Scholar]
40. Barbera R, Feinle C, Read NWAbnormal sensitivity to duodenal lipid infusion in patients with functional dyspepsia. Eur J Gastroenterol Hepatol. 1995;7:1051–1057.[PubMed][Google Scholar]
41. Barbera R, Feinle C, Read NWNutrient-specific modulation of gastric mechanosensitivity in patients with functional dyspepsia. Dig Dis Sci. 1995;40:1636–1641.[PubMed][Google Scholar]
42. Feinle C, Meier O, Otto B, D’Amato M, Fried MRole of duodenal lipid and cholecystokinin A receptors in the pathophysiology of functional dyspepsia. Gut. 2001;48:347–355.[Google Scholar]
43. Fried M, Feinle CThe role of fat and cholecystokinin in functional dyspepsia. Gut. 2002;51 Suppl 1:i54–i57.[Google Scholar]
44. Hopman WP, Jansen JB, Lamers CBComparative study of the effects of equal amounts of fat, protein, and starch on plasma cholecystokinin in man. Scand J Gastroenterol. 1985;20:843–847.[PubMed][Google Scholar]
45. Schwartz GJ, McHugh PR, Moran THGastric loads and cholecystokinin synergistically stimulate rat gastric vagal afferents. Am J Physiol. 1993;265:R872–R876.[PubMed][Google Scholar]
46. Chua AS, Dinan TG, Rovati LC, Keeling PWCholecystokinin hyperresponsiveness in dysmotility-type nonulcer dyspepsia. Ann N Y Acad Sci. 1994;713:298–299.[PubMed][Google Scholar]
47. Ford MJ, Camilleri M, Zinsmeister AR, Hanson RBPsychosensory modulation of colonic sensation in the human transverse and sigmoid colon. Gastroenterology. 1995;109:1772–1780.[PubMed][Google Scholar]
48. Mönnikes H, Tebbe JJ, Hildebrandt M, Arck P, Osmanoglou E, Rose M, Klapp B, Wiedenmann B, Heymann-Mönnikes I. Role of stress in functional gastrointestinal disorders. Evidence for stress-induced alterations in gastrointestinal motility and sensitivity. Dig Dis. 2001;19:201–211.[PubMed]
49. Dinan TG, Mahmud N, Rathore O, Thakore J, Scott LV, Carr E, Naesdal J, O'Morain CA, Keeling PWA double-blind placebo-controlled study of buspirone-stimulated prolactin release in non-ulcer dyspepsia--are central serotoninergic responses enhanced. Aliment Pharmacol Ther. 2001;15:1613–1618.[PubMed][Google Scholar]
50. Chua A, Keating J, Hamilton D, Keeling PW, Dinan TGCentral serotonin receptors and delayed gastric emptying in non-ulcer dyspepsia. BMJ. 1992;305:280–282.[Google Scholar]
51. Chua A, Ah-Kion S, Hamilton D, Dinan TG, Keeling PWAbnormal forebrain noradrenergic alpha-2 receptors functioning in patients with delayed gastric emptying. Ir J Med Sci. 1990;159:223.[PubMed][Google Scholar]
52. Chua A, Dinan TG, Weir DG, Keeling PWAbnormal cholecystokinin response in non-ulcer dyspeptic patients is associated with an abnormal central serotonergic and noradrenergic function. Hellenic J Gastroenterol. 1992;5:A189.[PubMed][Google Scholar]
53. Mayer EA, Craske M, Naliboff BDDepression, anxiety, and the gastrointestinal system. J Clin Psychiatry. 2001;62 Suppl 8:28–36; discussion 37.[PubMed][Google Scholar]
54. Naliboff BD, Mayer M, Fass R, Fitzgerald LZ, Chang L, Bolus R, Mayer EAThe effect of life stress on symptoms of heartburn. Psychosom Med. 2004;66:426–434.[PubMed][Google Scholar]
55. Gomez J, Dally PPsychologically mediated abdominal pain in surgical and medical outpatients clinics. Br Med J. 1977;1:1451–1453.[Google Scholar]
56. Magni G, di Mario F, Bernasconi G, Mastropaolo GDSM-III diagnoses associated with dyspepsia of unknown cause. Am J Psychiatry. 1987;144:1222–1223.[PubMed][Google Scholar]
57. Hill DR, Woodruff GNDifferentiation of central cholecys-tokinin receptor binding sites using the non-peptide antagonists MK-329 and L-365,260. Brain Res. 1990;526:276–283.[PubMed][Google Scholar]
58. Woodruff GN, Hill DR, Boden P, Pinnock R, Singh L, Hughes JFunctional role of brain CCK receptors. Neuropeptides. 1991;19 Suppl:45–56.[PubMed][Google Scholar]
59. Saito A, Sankaran H, Goldfine ID, Williams JACholecys-tokinin receptors in the brain: characterization and distribution. Science. 1980;208:1155–1156.[PubMed][Google Scholar]
60. Lindefors N, Linden A, Brene S, Sedvall G, Persson HCCK peptides and mRNA in the human brain. Prog Neurobiol. 1993;40:671–690.[PubMed][Google Scholar]
61. Stallone D, Nicolaïdis S, Gibbs JCholecystokinin-induced anorexia depends on serotoninergic function. Am J Physiol. 1989;256:R1138–R1141.[PubMed][Google Scholar]
62. Beresford IJ, Hall MD, Clark CR, Hill RG, Hughes JCholecystokinin modulation of [3H]noradrenaline release from superfused hypothalamic slices. Neurosci Lett. 1988;88:227–232.[PubMed][Google Scholar]
63. Crawley JNCholecystokinin-dopamine interactions. Trends Pharmacol Sci. 1991;12:232–236.[PubMed][Google Scholar]
64. Abelson JL, Nesse RM. Pentagastrin infusions in patients with panic disorder. I. Symptoms and cardiovascular responses. Biol Psychiatry. 1994;36:73–83.[PubMed]
65. Abelson JL, Nesse RM, Vinik AI. Pentagastrin infusions in patients with panic disorder. II. Neuroendocrinology. Biol Psychiatry. 1994;36:84–96.[PubMed]
66. Abelson JL, Liberzon IDose response of adrenocorticotropin and cortisol to the CCK-B agonist pentagastrin. Neuropsychopharmacology. 1999;21:485–494.[PubMed][Google Scholar]
67. Chua AS, Bekkering M, Rovati LC, Keeling PWClinical efficacy and prokinetic effect of the CCK-A antagonist loxiglumide in nonulcer dyspepsia. Ann N Y Acad Sci. 1994;713:451–453.[PubMed][Google Scholar]